ANALYSIS: With an Obermatt 360° View of 91 (better than 91% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Innate Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Innate Pharma. The consolidated Value Rank has an attractive rank of 83, which means that the share price of Innate Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 83% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 72, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 91. But the company’s financing is risky with a Safety rank of 33. This means 67% of comparable companies have a safer financing structure than Innate Pharma. ...read more